<p>WASHINGTON — An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about the safety of the&#
</p><p>An outside panel of FDA advisers will consider the staff's view during a meeting on Monday in which they will vote on whether the drug's benefits outweigh its risks, according&a
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: